Kisqali

País: Unión Europea

Idioma: inglés

Fuente: EMA (European Medicines Agency)

Ingredientes activos:

ribociclib succinate

Disponible desde:

Novartis Europharm Limited

Código ATC:

L01XE

Designación común internacional (DCI):

ribociclib

Grupo terapéutico:

Antineoplastic agents

Área terapéutica:

Breast Neoplasms

indicaciones terapéuticas:

Kisqali is indicated for the treatment of women with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist.

Resumen del producto:

Revision: 14

Estado de Autorización:

Authorised

Fecha de autorización:

2017-08-22

Información para el usuario

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Kisqali 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains ribociclib succinate, equivalent to
200 mg ribociclib.
Excipients with known effect
Each film-coated tablet contains 0.344 mg soya lecithin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light greyish violet, unscored, round, curved with bevelled edges
(approximate diameter: 11.1 mm),
debossed with “RIC” on one side and “NVR” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Kisqali is indicated for the treatment of women with hormone receptor
(HR)-positive, human
epidermal growth factor receptor 2 (HER2)-negative locally advanced or
metastatic breast cancer in
combination with an aromatase inhibitor or fulvestrant as initial
endocrine-based therapy, or in women
who have received prior endocrine therapy.
In pre- or perimenopausal women,
_ _
the endocrine therapy should be combined with a luteinising
hormone-releasing hormone (LHRH) agonist.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with Kisqali should be initiated by a physician experienced
in the use of anticancer
therapies.
Posology
The recommended dose is 600 mg (three 200 mg film-coated tablets) of
ribociclib once daily for
21 consecutive days followed by 7 days off treatment, resulting in a
complete cycle of 28 days. The
treatment should be continued as long as the patient is deriving
clinical benefit from therapy or until
unacceptable toxicity occurs.
Kisqali should be used together with 2.5 mg letrozole or another
aromatase inhibitor or with 500 mg
fulvestrant.
3
When Kisqali is used in combination with an aromatase inhibitor, the
aromatase inhibitor should be
taken orally once daily continuously throughout the 28-day cycle.
Please refer to the Summary of
Product Characteristics (SmPC) of the aromatase inhibitor for
additional details.
When Kisqali is used in combination with fulvest

Ficha técnica

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Kisqali 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains ribociclib succinate, equivalent to
200 mg ribociclib.
Excipients with known effect
Each film-coated tablet contains 0.344 mg soya lecithin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light greyish violet, unscored, round, curved with bevelled edges
(approximate diameter: 11.1 mm),
debossed with “RIC” on one side and “NVR” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Kisqali is indicated for the treatment of women with hormone receptor
(HR)-positive, human
epidermal growth factor receptor 2 (HER2)-negative locally advanced or
metastatic breast cancer in
combination with an aromatase inhibitor or fulvestrant as initial
endocrine-based therapy, or in women
who have received prior endocrine therapy.
In pre- or perimenopausal women,
_ _
the endocrine therapy should be combined with a luteinising
hormone-releasing hormone (LHRH) agonist.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with Kisqali should be initiated by a physician experienced
in the use of anticancer
therapies.
Posology
The recommended dose is 600 mg (three 200 mg film-coated tablets) of
ribociclib once daily for
21 consecutive days followed by 7 days off treatment, resulting in a
complete cycle of 28 days. The
treatment should be continued as long as the patient is deriving
clinical benefit from therapy or until
unacceptable toxicity occurs.
Kisqali should be used together with 2.5 mg letrozole or another
aromatase inhibitor or with 500 mg
fulvestrant.
3
When Kisqali is used in combination with an aromatase inhibitor, the
aromatase inhibitor should be
taken orally once daily continuously throughout the 28-day cycle.
Please refer to the Summary of
Product Characteristics (SmPC) of the aromatase inhibitor for
additional details.
When Kisqali is used in combination with fulvest